Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years.
• Histological confirmed adenocarcinoma of the breast stage I-IV from the American Joint Committee on Cancer staging 8th edition.
• Any ER or PR but HER2 positive defined as 3+ staining intensity (on a scale of 0 to 3) by means of IHC analysis OR gene amplification on fluorescence in situ hybridization (FISH) ratio ≥ 2.0.
• Scheded to start new anti=HER2 therapy/therapies.
• Provide written informed consent.
• Willingness to provide blood samples for correlative research purposes.

Exclusion Criteria: 

• Immunocompromised patients including patients known to be HIV positive.
• Receiving systemic steroid therapy or any other immunosuppressive therapy ≤ 30 days prior to registration. NOTE: Inhaled steroids, low-dose corticosteroids (e.g., equivalent to or less than oral prednisone 10 mg daily), and steroid use for primary prevention of nausea per institutional guidelines are allowed.